Abbott's Device Strength Tempered by Integration Overhang

What happened

Abbott's medical devices segment posted strong 8.5% Q1 growth, led by electrophysiology (+12.5%), rhythm management, and heart failure, underpinning the company's long-term growth strategy. However, the $20.6B Exact Sciences acquisition is pressuring near-term results: SG&A surged $679M YoY, diagnostics growth remains tepid (Rapid & Molecular -9.6% ex-FX), and the stock has fallen ~29% from its peak. The market is focused on whether device momentum can offset integration dilution through 2027, with guided adjusted EPS headwinds of -$0.20 in 2026. While the device engine is intact, the overhang from rising costs and diagnostics weakness keeps the story in a 'show-me' phase. Clear evidence of SG&A normalization and CGM acceleration beyond mid-single digits is needed before re-rating.

Implication

Medical devices remain a durable growth engine (CGM, cardio), but full value realization hinges on successful Exact Sciences integration and CGM reimbursement expansion. Monitor SG&A trends and quarterly diagnostics performance; conviction can improve if CGM >10% ex-FX and SG&A declines sequentially.

Thesis delta

The news reinforces the device growth narrative already reflected in the base case, but does not alter the core concerns about integration costs and diagnostics weakness. The thesis remains cautious with a 'WAIT' rating; no upgrade until operating evidence de-risks the near-term cost structure.